Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 34.54 -6.70% -2.48
DCPH closed down 6.7 percent on Thursday, May 6, 2021, on 3.35 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical DCPH trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Volume Surge Other 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Older End-of-Day Signals for DCPH ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
3x Volume Pace about 14 hours ago
Down 1 ATR about 15 hours ago
2x Volume Pace about 16 hours ago
60 Minute Opening Range Breakdown about 16 hours ago
1.5x Volume Pace about 16 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Deciphera Pharmaceuticals, Inc. Description

Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Development Immune System Drugs Gastrointestinal Cancer Treatments Blastoma Antineoplastic Drugs Targeted Therapy Glioblastoma Tyrosine Kinase Receptors Platelet Protein Kinase Inhibitor Gastrointestinal Stromal Tumor Glioblastoma Multiforme Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumors Tie2 Treatment For Cancer

Is DCPH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 68.4
52 Week Low 33.5501
Average Volume 404,387
200-Day Moving Average 50.68
50-Day Moving Average 44.03
20-Day Moving Average 44.89
10-Day Moving Average 44.16
Average True Range 2.68
ADX 19.51
+DI 9.77
-DI 39.05
Chandelier Exit (Long, 3 ATRs ) 40.24
Chandelier Exit (Short, 3 ATRs ) 41.58
Upper Bollinger Band 51.55
Lower Bollinger Band 38.22
Percent B (%b) -0.28
BandWidth 29.69
MACD Line -1.19
MACD Signal Line 0.04
MACD Histogram -1.2261
Fundamentals Value
Market Cap 1.97 Billion
Num Shares 56.9 Million
EPS -3.31
Price-to-Earnings (P/E) Ratio -10.43
Price-to-Sales 144.28
Price-to-Book 6.01
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.47
Resistance 3 (R3) 40.80 39.15 39.48
Resistance 2 (R2) 39.15 37.64 38.99 39.15
Resistance 1 (R1) 36.85 36.71 36.02 36.52 38.82
Pivot Point 35.20 35.20 34.79 35.03 35.20
Support 1 (S1) 32.89 33.69 32.07 32.56 30.26
Support 2 (S2) 31.24 32.75 31.08 29.93
Support 3 (S3) 28.94 31.24 29.60
Support 4 (S4) 28.61